Previous Article | Next Article ![]()
Infection and Immunity, January 2000, p. 270-280, Vol. 68, No. 1
Department of Veterinary Microbiology and
Pathology, Washington State University, Pullman, Washington 99164-7040
Received 25 June 1999/Returned for modification 5 August
1999/Accepted 11 October 1999
Anaplasma marginale is a tick-transmitted pathogen of
cattle closely related to the human ehrlichiae, Ehrlichia
chaffeensis and the agent of human granulocytic ehrlichiosis
(HGE). These pathogens have in common a structurally conserved outer
membrane protein (OMP) designated the major surface protein 2 (MSP-2)
in A. marginale and HGE and OMP-1 in E. chaffeensis. Protective immunity against ehrlichial pathogens is
believed to require induction of gamma interferon (IFN- Anaplasma marginale is an
important tick-transmitted rickettsial pathogen of cattle that invades
and multiplies within erythrocytes, causing severe hemolytic anemia
during acute infection. Recovery from acute disease leads to a state of
persistent infection and allows subsequent transmission to
immunologically naïve cattle. At least six outer membrane
proteins (OMP) of A. marginale have been described (32,
34), and major surface protein 2 (MSP-2) is among the most
immunodominant surface antigens. A. marginale is a member of
the ehrlichial genogroup II, and MSP-2 shares significant structural
and sequence homology with OMP homologues of other ehrlichiae. These
include members of genogroup II, most notably the agent of human
granulocytic ehrlichiosis (HGE), and the genogroup I pathogens
Ehrlichia chaffeensis and Cowdria ruminantium
(14, 18, 27, 30, 36, 51, 53).
Immunization with native MSP-2 derived from the Florida strain of
A. marginale resulted in partial to complete protection in
cattle challenged with homologous or heterologous strains
(31). Immunization with outer membranes of A. marginale also provided protection to 70% of calves, and
protection correlated with titers of antibody against MSP-2
(46). Furthermore, members of our group recently
demonstrated complete protection against infection following homologous
challenge in calves immunized with purified outer membranes of the
Florida strain with saponin as an adjuvant (7). Complete
protection was associated with development of immunoglobulin G2 (IgG2)
responses directed predominantly against MSP-2 and with the production
of gamma interferon (IFN- CD4+ T cells are important for immunity against
intraerythrocytic pathogens by activating macrophages through the
production of IFN- IL-12 is a cytokine that when used as an adjuvant with a protein
antigen can augment protective immunity against intracellular pathogens
by stimulating IFN- Preparation of A. marginale antigens.
A
splenectomized Holstein calf was infected with A. marginale
(Florida strain) to propagate organisms for preparation of outer membranes and purified MSP-2. Native MSP-2 was gel purified to ensure
that all of the potentially expressed MSP-2 copies in the Florida
strain were represented in the immunogen. A. marginale organisms were isolated from thawed, infected bovine erythrocytes by
sonication and differential ultracentrifugation as previously described
(33), suspended in electrophoresis sample buffer, and
separated on multiple preparative sodium dodecyl sulfate (SDS)-10% polyacrylamide gels. One gel was transferred and blotted with MSP-2-specific monoclonal antibody (MAb) as described previously (31) to orient the MSP-2 on the preparative gels. The MSP-2 band was excised from multiple gels, and the protein was electroeluted from the gel fragments as described previously (29). Eluted protein was concentrated and dialyzed against PBS (pH 7.2) and repurified a second time on preparative gels. Figure
1 shows the result of a SDS-12%
polyacrylamide gel electrophoresis (SDS-12% PAGE) analysis of 3 µg
of gel-purified MSP-2 used for inoculation. MSP-2 was verified by
immunoblotting to be reactive with the antibodies specific for MSP-2
but unreactive with antibodies to other A. marginale MSP
(data not shown).
0019-9567/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Interleukin-12 as an Adjuvant Promotes
Immunoglobulin G and Type 1 Cytokine Recall Responses to Major Surface
Protein 2 of the Ehrlichial Pathogen Anaplasma
marginale

![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
) and
opsonizing immunoglobulin (Ig) subclasses directed against OMP epitopes
that, in concert, activate macrophages for phagocytosis and killing.
Because interleukin-12 (IL-12) acts as an adjuvant for protein
immunization to induce IFN-
and protective immunity against
intracellular pathogens, we hypothesized that as an adjuvant with
MSP-2, IL-12 would augment type 1 recall responses to A. marginale. IL-12 was coadsorbed with MSP-2 to alum and shown to
significantly enhance IFN-
production by lymph node cells (LNC) and
LNC-derived CD4+ T-cell lines from immunized calves
following recall stimulation with A. marginale. LNC
proliferation and IL-2 production were also enhanced in IL-12-treated
calves. Elevated recall proliferative responses by peripheral blood
mononuclear cells were still evident 9 months after immunization. Serum
IgG levels were consistently increased in IL-12 immunized calves,
predominantly due to higher IgG1 responses. The results support the use
of IL-12 coadsorbed with OMP of ehrlichial pathogens in alum to amplify
both antibody and type-1 cytokine responses important for protective immunity.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
) by antigen-specific T cells. Several
cloned CD4+ T-cell lines derived from the protected cattle
were MSP-2 specific, but not strain specific, suggesting recognition of
MSP-2 T-cell epitopes conserved among strains (9). This
conservation is notable given the extensive structural variation
encoded by the msp2 gene family, both within and between
strains (15, 31, 34, 39). Thus, such conserved T-cell
epitopes may be useful components of a subunit or nucleic acid vaccine
designed to induce protective immunity against multiple strains of
A. marginale.
(44) and by promoting enhanced IgG
production (6). The importance of IFN-
in protection
against anaplasmosis has been recently reviewed (34).
Briefly, in cattle IFN-
enhances IgG2 production (6, 10),
and activates macrophages to produce molecules, such as nitric oxide
(NO), that are toxic for intraerythrocytic pathogens (references
20 and 44; L. K. M. Shoda, J. Florin-Christenson, M. Florin-Christenson, G. H. Palmer,
and W. C. Brown, submitted for publication). In vitro incubation
with A. marginale-immune serum neutralized the infectivity
of A. marginale for cattle (33), and IgG2 may be
involved in neutralization because of its superior ability to promote
phagocytosis through opsonization (25). For these reasons,
adjuvants that stimulate the production of IFN-
during antigen
priming and IgG antibodies are predicted to enhance protective immune responses.
production (1, 26). Numerous studies
in mice have verified that interleukin-12 (IL-12), produced by
dendritic cells and other antigen-presenting cells (APC) during T-cell
priming, promotes a biased or enhanced Th1 cytokine response (17,
24, 40, 41, 43, 45, 47). When adsorbed together with a soluble
protein in aluminum hydroxide (alum), IL-12 stimulated a polarized type
1 cytokine response but enhanced both type 1 (IgG2 and IgG3) and type 2 (IgG1) antibody responses in mice (19). Adsorption of IL-12
to alum appeared critical for maintaining serum IFN-
levels, likely
by prolonging the in vivo half-life of IL-12. Recently, it was
demonstrated that the recall T-cell response to a protein antigen
administered with IL-12 in phosphate buffered saline (PBS) during the
primary antigen inoculation featured the type 1 cytokine and antibody
responses observed immediately after priming. Interestingly, the memory
response to antigen was additionally characterized by the development
of type 2 cytokine and antibody responses not observed after priming
(3). In vivo experiments performed with IL-12 as an adjuvant
for cattle have not been reported. However, IL-12 stimulated enhanced
IFN-
production by mitogen- or antigen-stimulated bovine peripheral
blood mononuclear cells (PBMC) and antigen-stimulated effector
CD4+ T-cell clones (4). Furthermore, when added
during in vitro activation and differentiation of memory T cells
cultured with antigen, IL-12 induced production of IFN-
that was
significantly enhanced compared to that of cells cultured without
exogenous IL-12 (49). In the present study, we hypothesized
that IL-12 administered as an adjuvant to cattle with MSP-2 by
coadsorption to alum would prime for enhanced type 1 recall responses
characterized by increased production of IFN-
in response to
A. marginale stimulation by memory or effector
CD4+ T cells. We observed that IL-12 stimulated enhanced
IFN-
and IL-2 secretion and transcript expression by antigen-primed
lymph node cells (LNC) as well as enhanced serum IgG1 titers.
Transcript levels of IL-4 and IL-10 were also elevated in LNC from
IL-12-primed calves. Contrary to what was predicted, IL-12 did not
uniformly stimulate IgG2 production, and the upregulation of IgG2 by
one calf given IL-12 was not associated with high levels of IFN-
production. These data suggest that factors in addition to IFN-
may
be important for promoting isotype switching to IgG2.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (53K):
[in a new window]
FIG. 1.
SDS-PAGE analysis of gel-purified native MSP-2 from the
Florida strain of A. marginale. MSP-2 (3 µg) was
visualized on a Coomassie blue-stained 12% acrylamide gel (arrow).
Molecular masses are indicated on the right of the gel.
Cattle and immunization with MSP-2.
Nine age-matched
Holstein steers 4 to 5 months old and weighing approximately 150 to 200 kg at the start of the experiment were verified to be serologically
negative for A. marginale by competitive inhibition
enzyme-linked immunosorbent assay (ELISA) (21) and were
assigned randomly to three groups. All calves received six 2-ml
subcutaneous inoculations in the right and left sides of the neck as
detailed in Table 1. Calves were
administered alum and IL-12 (group I); alum and MSP-2 (group II); or
alum, MSP-2, and IL-12 (group III). Human recombinant IL-12 was kindly provided by Genetics Institute, Inc., Cambridge, Mass. The dosage of
IL-12 (approximately 50 ng/kg of body weight) used was 10-fold less
than that used in human trials where toxicity was observed (22). In initial inoculations, 20 µg of MSP-2 was given,
since this amount of antigen induced vigorous responses in other
immunization studies (reference 37; W. C. Brown, T. C. McGuire, and G. H. Palmer, unpublished
observations). After two injections, the amount of MSP-2 was increased,
since weak antibody and proliferation responses were generated.
Gel-purified MSP-2 and/or IL-12 was adsorbed in 20 mg of alum
(Rehydragel, low viscosity sterile gel; Reheis, Inc., Berkeley Heights,
N.J.) in 2 ml of sterile PBS according to the manufacturer's
instructions. Serum samples and PBMC were collected before and at 2 weeks following each inoculation and assayed for A. marginale-specific antibody and proliferation, respectively. Once
specific lymphocyte proliferation was observed, the animals were given
a final antigen inoculation and the antigen-draining (right) and
contralateral (left) prescapular lymph nodes (LN) were surgically
biopsied to remove approximately one half of the LN. The timing of the
sixth inoculation was staggered so that one calf per group was used at
each time point (Table 1). LNC suspensions were prepared
(38) and either were used immediately for proliferation
assays, surface phenotype analysis, and cytokine determination or were
cryopreserved in liquid nitrogen in a solution of 10%
dimethylsulfoxide in fetal bovine serum.
|
Analysis of A. marginale-specific IgG1 and IgG2 responses. SDS-PAGE and immunoblotting were performed with MAb specific for bovine IgG, IgG1, and IgG2 to determine the appearance of MSP-2-specific antibody and the subclass of the specific IgG response. The procedures were performed as described recently (7), with the following modifications. A. marginale (Florida strain) homogenate (100 µg of protein) was applied in a single lane to a 7.5 to 17.5% polyacrylamide gradient gel and electrophoresed, and the proteins were transferred to nitrocellulose membranes. The membranes were air-dried and immersed for 2 h in blocking solution consisting of PBS (pH 7.4) supplemented with 0.02% sodium azide, 0.1% Tween 20, and 10% normal horse serum (Vector Laboratories, Inc., Burlingame, Calif.) with gentle agitation. Following extensive washing in PBS-Tween (PBS [pH 7.4]-0.02% sodium azide-0.1% Tween 20), the membranes were placed in a Miniblotter 25 apparatus (Immunetics, Cambridge, Mass.) and 250 µl of bovine sera serially diluted (1:100 to 1:100,000) in blocking solution per well was added according to the manufacturer's protocol. The membranes were incubated for 2 h at room temperature on a rocking platform. Following successive washes in PBS-Tween with 0.1% NP-40 and PBS-Tween alone, the membranes were incubated overnight at 4°C and for an additional 1.5 h at room temperature on a rocker platform with murine anti-bovine IgG, IgG1, or IgG2 MAb (Serotec Ltd., Oxford, United Kingdom) diluted 1:100 in PBS-Tween with 2% horse serum. The membranes were washed extensively, and the reaction mixtures were then labeled for 1 h at room temperature with peroxidase-conjugated affinity-purified donkey anti-mouse IgG (heavy plus light chains; Jackson Immunoresearch Laboratories, West Grove, Pa.) diluted 1:5,000 in TNT buffer containing 1% horse serum. The membranes were washed repeatedly with TNT buffer, and the chemiluminescence was developed with a Renaissance Western blot chemiluminescence reagent (NEN Life Science Products, Boston, Mass.) according to the manufacturer's instructions.
A. marginale-specific T-cell lines. Short-term T-cell lines were established from PBMC of A. marginale MSP-2-immunized calves from 3 to 5 weeks following the fifth immunization or from cryopreserved LNC. Briefly, 4 × 106 PBMC or LNC per well were cultured in 24-well plates (Costar, Cambridge, Mass.) in 1.5 ml of complete RPMI 1640 medium (5) with 3 to 5 µg of A. marginale membrane antigen per ml. After 7 days, cells were subcultured to a density of 5 × 105 cells per well and cultured with antigen and 2 × 106 irradiated (3,000 rads) autologous PBMC as a source of APC. T-cell lines were maintained for up to 5 weeks by weekly stimulation with antigen and APC, and cells were assayed for antigen-dependent proliferation 7 days following the last stimulation.
Lymphocyte proliferation assays.
Proliferation assays were
carried out in replicate wells of round-bottomed 96-well plates
(Costar) for 5 to 6 days when PBMC were used or for 4 days when LNC or
short-term T-cell lines were used, essentially as described previously
(7, 9). PBMC or LNC (2 × 105) were
cultured in triplicate wells with antigen in a total volume of 100 µl
of complete medium. T-cell lines were assayed 7 days after the last
stimulation with antigen and APC. T-cell lines (3 × 104 cells) were cultured in duplicate wells in a total
volume of 100 µl of complete medium containing 2 × 105 APC and antigen. Antigens consisted of 0.2 to 25.0 µg
of A. marginale Florida homogenate or membranes per ml, and
as a control, membranes prepared from uninfected bovine red blood cells
(URBC) (6) were used. Protein concentrations in all antigen
preparations were determined by the Bradford assay. To determine
proliferation, cells were radiolabeled for the last 18 h of
culture with 0.25 µCi of [3H]thymidine (Dupont New
England Nuclear, Boston, Mass.), radiolabeled nucleic acids were
harvested onto glass filters, and radionucleotide incorporation was
measured with a Betaplate 1205 liquid scintillation counter (Wallac,
Gaithersburg, Md.). Results presented are the mean number of counts per
minute of replicate cultures ± the standard error of the mean
(SEM) or the stimulation index (SI), which represents the mean number
of counts per minute of replicate cultures of cells plus antigen/the
mean number of counts per minute of replicate cultures of cells plus
medium or URBC. An SI of
2.0 was considered statistically significant.
Cell-surface phenotypic analysis.
Differentiation markers on
LNC and T-cell lines were analyzed by indirect immunofluorescence and
flow cytometry as previously described (8). The MAbs used
were specific for bovine CD2 (MAb MUC2A), CD3 (MAb MM1A), CD4 (MAb CACT
138A), CD8 (MAbs CACT 80C and BAT 82B), and the
chain of the
/
T-cell receptor (TcR) (MAb CACT 61A). These MAbs were kindly
provided by William C. Davis, Washington State University, Pullman, Wash.
Detection of IFN-
and IL-2 in supernatants of LNC and T-cell
lines.
Fresh LNC were cultured for 96 h in complete medium
with 5 µg of A. marginale membrane antigen per ml, and
supernatants were collected at 72 (first set of calves) or 96 h.
T-cell lines were established from cryopreserved, antigen-draining LNC
of calves in groups II and III by weekly stimulation with membrane
antigen and APC. After 3 weeks, the cells were washed and cultured for 48 h at a density of 2 × 106 cells per ml with
2 × 106 APC per ml and 3 µg of membranes prepared
from the Florida strain of A. marginale per ml. Supernatants
were harvested by centrifugation and stored frozen at
20°C. The
bovine IFN-
assay was performed with a commercial ELISA kit
(BOVIGAM; CSL Limited, Parkville, Victoria, Australia) according to the
manufacturer's protocol. The IFN-
activity in culture supernatants
diluted 1:5 to 1:2,000 was determined by comparison with a standard
curve obtained with a supernatant from a Mycobacterium bovis
purified protein derivative-specific Th cell clone that contained 440 U
of IFN-
per ml (previously determined by the neutralization of
vesicular stomatitis virus [8]). In our assay, 0.6 U
corresponds to 1 ng of IFN-
(2). The results are
presented in units or nanograms of IFN-
per milliliter. The IL-2
bioassay was performed as described previously (48) in
triplicate with supernatants diluted 1:2 with an IL-2-dependent bovine
CD8+ T-cell clone (G4.3D1) for responder cells and
recombinant human IL-2 (Boehringer Mannheim) as a standard. The results
are presented in picograms of IL-2 produced per milliliter of cell supernatant.
Analysis of neutralizing antibody against human IL-12.
Heat-inactivated sera obtained from calves before and following the
third inoculation of MSP-2 and IL-12 were serially diluted from 1:200
to 1:64,000 and tested for neutralization of human IL-12. An IL-12
bioassay based on induction of IFN-
by IL-12- and phytohemagglutinin
(PHA)-stimulated PBMC was used (42). Diluted sera were
incubated with 0.02 ng of IL-12 at 37°C for 1 h and then added
along with 1 µg of PHA (Sigma Chemical Co.) to 2 × 106 PBMC cultured in 1 ml of complete medium. Supernatants
were harvested 48 h later and tested for IFN-
by ELISA. At
dilutions of 1:200 or greater, preimmunization sera had no inhibitory
activity. As a positive control, serial dilutions of goat anti-human
IL-12 IgG (R & D Systems, Minneapolis, Minn.) were also mixed with 0.02 ng of IL-12 and tested for induction of IFN-
, and the dose that neutralized 50% of the biological activity (ND50) was 0.5 µg.
QC-RT-PCR analysis of cytokine transcripts in the LNC from
immunized calves.
As ELISA-based assays to quantify bovine IL-4
and IL-10 are not commercially available, quantitative, competitive
reverse transcription-PCR (QC-RT-PCR) analysis of cytokine mRNA was
performed. RNA was prepared from antigen-draining and contralateral
prescapular LNC from all calves prior to or following culture for 6 or
12 h of 2.7 × 106 cells per ml with 5 µg of
A. marginale membrane antigen per ml. Total cellular RNA was
extracted using the Trizol reagent (GIBCO-BRL, Gaithersburg, Md.), and
RNA samples were stored at
80°C. QC-RT-PCR was performed as
described previously (48-50), with minor modifications. Briefly, competitor molecules (mimics) for bovine IL-2, IL-4, IL-10,
and IFN-
were kindly provided by Dante Zarlenga (Department of
Immunobiology and Disease Resistance, U.S. Department of Agriculture, Agriculture Research Service, Beltsville, Md.), and the bovine
-actin mimic was generated in our laboratory as described by Zarlenga et al. (52). The primer sequences used to amplify
the cytokine cDNAs were exactly as described previously
(48-50), with the exception of the IL-2 reverse primer, for
which the correct sequence is 5' TCA AGT CAT TGT TGA GTA GAT GCT T
3'. The resultant IL-2, IL-4, IL-10, IFN-
, and
-actin
competitor PCR fragments were distinguishable from native fragments by
their smaller size (48, 50). Column-purified, RNA-free
plasmids containing cytokine competitors were serially diluted 10-fold
with sterile double-distilled water and stored at
20°C until used.
Total RNA (0.5 to 1.0 µg) was reverse-transcribed to cDNA in a
20-µl volume by using oligo(dT)16 (Perkin Elmer,
Branchburg, N.J.) according to the manufacturer's instructions. For
each sample tested, PCRs were performed, with each reaction mixture
containing PCR primers; mimic DNA (0.1 to 1000 fg); cDNA (0.05 to 5 ng); a master mixture containing 10× PCR buffer (final concentration,
1×), magnesium (final concentration, 2.5 mM), and deoxynucleoside
triphosphates (final concentration, 1 mM); AmpliTaq-Gold (1 U per
reaction mixture; Perkin-Elmer); and water in a 50-µl volume. The PCR
mixture was preheated to 94°C for 10 min to activate the
AmpliTaq-Gold, followed by 35 cycles of amplification under the
following conditions: 94°C for 1 min, 60°C for 1 min, and 72°C
for 2 min. The reactions were completed by an extension at 72°C for
10 min and stored at 4°C until analyzed. PCR products (20 µl) were
electrophoresed on a 1% agarose gel containing ethidium bromide and
quantified under UV light using a digital imaging system (IS1000; Alpha
Innotech Corporation, San Leandro, Calif.). After correcting for
differences in molecular weight between native and competitor DNA, the
ratios between the amplified products of the target and competitor
sequences at each competitor concentration were calculated. The logs of the ratios were plotted against the input concentrations of competitor DNA, and a regression equation was obtained. At the point of
equivalence, where the amplified target/competitor DNA ratio equals
1.0, the amount of cytokine cDNA in the test sample equals the amount
of competitor DNA. To compare the amount of cytokine mRNA in different samples, cytokine mRNA levels were normalized to the amount of
-actin. Genomic DNA was not detected for any cytokine or
-actin in the RNA samples. Results are presented in femtograms of cytokine RNA
per microgram of total cellular RNA.
Statistical analysis.
A one-tailed, nonpaired Student's
t test was used to compare the mean levels of proliferation,
IFN-
production, and steady-state cytokine transcript levels in LNC
for the groups of calves. A one-tailed, paired Student's t
test was used to compare these parameters for right and left
prescapular LN in the different groups. A P value of
0.05
was considered significant.
| |
RESULTS |
|---|
|
|
|---|
A. marginale-specific proliferation in PBMC of MSP-2-immunized calves. Calves were immunized, as detailed in Table 1, at 3- to 4-week intervals with gel-purified native MSP-2 antigen in alum and with or without IL-12 until specific proliferation was observed. PBMC were tested after each immunization for proliferation against several concentrations of membrane antigen prepared from A. marginale (Florida strain) or control URBC. Calf 61, which received MSP-2 and IL-12, responded after the third inoculation, whereas the remaining calves in both immunized groups did not respond until after the fifth antigen inoculation, at 17 or 18 weeks. The responses were variable, with those of calves 63 and 59 being the weakest (Fig. 2). Control calves that did not receive MSP-2 failed to respond to A. marginale or URBC at any time point (data not shown).
|
/
T cells (data not
shown). Specific proliferation was observed in all four cell lines
after 1 and 2 weeks of culture (Table 2),
and responses to URBC were not significant (data not shown). However,
repeated attempts to propagate cell lines from PBMC of animals 63 and
65 in group II were unsuccessful.
|
IgG responses in calves immunized with MSP-2 or MSP-2 and
IL-12.
Serological responses were monitored throughout the
immunization by Western blot analysis. All preimmunization sera and
control sera from calves immunized with alum and IL-12 were negative
for reactivity on the immunoblots (data not shown). IgG responses in
all three calves that received IL-12 and MSP-2 were detected at the
first time point tested, 2 weeks following the second antigen inoculation (week 6), whereas only one of three calves inoculated with
MSP-2 alone was seropositive (data not shown). The other two calves in
the MSP-2 only group seroconverted after the third (week 10) and fourth
(week 13) antigen injections. The sera reacted with a 36-kDa band on
the immunoblots, which coincides with the molecular mass of MSP-2.
Analysis of IgG1- and IgG2-specific titers in sera obtained 2 weeks
after the fifth inoculation of antigen showed that the calves immunized
with IL-12 made significantly more IgG1 than the calves that received
MSP-2 alone (Table 3). Furthermore, one
of three calves in the IL-12 group produced IgG2.
|
Analysis of antigen-induced proliferation and cytokine production
by draining LN lymphocytes.
Once A. marginale-specific
proliferative and serological responses were detected, the calves were
given a final antigen inoculation so that antigen-draining (right) and
contralateral (left) lymph nodes could be surgically biopsied for
examination of antigen-induced recall responses. The booster
inoculation was staggered so that one calf from each group was used for
each of three time points (Table 1). The relative percentages of T-cell
subsets in the LN were similar in all groups (Table
4).
|
|
and
IL-2 production (Fig. 4). Significantly
more IFN-
was produced by the antigen-draining (right) LNC of group
III calves that received IL-12 and MSP-2 than by group I control calves
or group II calves immunized with MSP-2 alone. Furthermore, for group
III calves, the antigen-draining right LNC secreted higher levels of
IFN-
than the contralateral LNC. Higher levels of IL-2 were also
produced by LNC from group III calves immunized with MSP-2 and IL-12.
Increased IL-2 production by group III calves is consistent with their
stronger proliferative responses to antigen (Fig. 3).
|
Cytokine transcript expression by antigen-draining and
contralateral LNC.
To verify the adjuvant effect of IL-12 on
enhancing IL-2 and IFN-
production and to examine other cytokines
important for priming and immune regulation, QC-RT-PCR analysis of
IL-2, IFN-
, IL-4, and IL-10 transcript expression was performed with
RNA obtained from LNC of all calves. RNA was obtained from freshly
collected LNC or following stimulation with A. marginale for
6 or 12 h. In MSP-2-immunized calves, the amount of cytokine
transcript determined by RT-PCR increased following antigen activation
(data not shown), so RNA from the 12-h time point was selected for use
in QC-RT-PCR. For both MSP-2-immunized groups, comparison of the mean
transcript levels in antigen-draining (right) LNC and contralateral
(left) LNC revealed higher transcript levels in the antigen-draining LNC (Fig. 5). Calves given MSP-2 and
IL-12 (group III) had the highest mean levels of transcripts in both
antigen-draining (right) and contralateral (left) LNC. When the mean
levels of transcripts were compared, group III calves had approximately
ninefold more IL-2 and fourfold more IFN-
than the calves immunized
with MSP-2 alone (group II). Although the difference in IFN-
transcript levels between group II and III calves was not significant
due to the low response of calf 59, calves 60 and 61 had IFN-
transcript levels well above 95% confidence limits of the mean IFN-
values for group II calves. IL-4 and IL-10 transcripts were absent or were present at levels that were relatively low in all calves but
higher in the group III calves than in group II calves. Overall, the
relative steady-state levels of IL-2 and IFN-
transcripts analyzed
using QC-RT-PCR were consistent with the relative amount of cytokine
product determined by bioassay or ELISA. Collectively, these data
demonstrate that immunization with IL-12 augments the production of
IL-2 and IFN-
during a recall response to antigen.
|
Neutralizing antibody to human IL-12.
The variable cytokine
responses among calves immunized with MSP-2 and IL-12 (Fig. 4 and 5)
raised the possibility that the differences might correlate with the
presence of neutralizing antibodies to human IL-12. By an IL-12
bioassay consisting of costimulation of bovine PBMC with 0.02 ng of
IL-12 and 1 µg of PHA, which stimulated production of approximately
150 U of IFN-
per ml (data not shown), serially diluted bovine sera
had ND50 titers of 2,506 (calf 59), 2,512 (calf 60), and
1,932 (calf 61). Thus, although three immunizations of human IL-12 did
elicit neutralizing antibodies to human IL-12, the ND50
titers did not correlate with the different levels of cytokine
expression among group III calves.
Antigen-induced proliferation and IFN-
production by short-term
T-cell lines established from antigen-draining LNC.
We next wished
to determine if effector cells cultured from the antigen-draining LN
maintained the type 1 cytokine phenotype for several weeks. Short-term
T-cell lines were established from all three group III calves and from
group II calf 63 by weekly stimulation of LNC with A. marginale membrane antigen and APC. We were unable to establish
vigorously growing cell lines from group II calves 57 and 65, so after
the 3-week culture period, only enough cells were available to test for
IFN-
production. The inability to propagate cells from these animals
is consistent with the low or absent proliferation of these LNC (Fig.
3). All four cell lines that were expanded were comprised mainly of
CD4+ T cells (93 to 95%). In proliferation assays these
four cell lines responded similarly to A. marginale, after 1 to 3 weeks of culture (data not shown). However, cell lines from MSP-2-
and IL-12-immunized calves produced significantly more IFN-
(Table 5).
|
Duration of the memory response to A. marginale. To determine if immunization with MSP-2 and IL-12 elicited long-term immunological memory, PBMC obtained from all six MSP-2-immunized calves 9 months after the last group was boosted with MSP-2 were tested for antigen-specific proliferation. Dose-dependent and specific responses to A. marginale homogenate were observed in two MSP-2-immunized and all three MSP-2- and IL-12-immunized calves, with the highest responses observed in calves that received IL-12. The SI values in response to the optimal antigen concentration (5 or 25 µg of protein per ml) for group II calves 57, 63, and 65 were 2.6, 3.1, and 1.3, and those for group III calves 59, 60, and 61 were 4.6, 3.6, and 27.7, respectively, which values are representative of two experiments. The lack of response by PBMC from calf 65 is consistent with the lack of a recall response in the antigen-draining LNC (Fig. 3).
| |
DISCUSSION |
|---|
|
|
|---|
This study is the first to examine CD4+ T-cell responses in cattle immunized with native MSP-2 antigen. We demonstrated specific and long-lived recognition of purified A. marginale membranes or organism homogenate from the homologous Florida strain by CD4+ T cells from PBMC and LNC, showing that MSP-2 is capable of priming for an anamnestic T-cell response to the organism. These data are consistent with earlier studies which showed that PBMC and several CD4+ T cell clones obtained from calves immunized with purified A. marginale membranes responded to organism homogenate, purified outer membranes, and MSP-2 (7, 9). MSP-2 and related proteins, including the OMP of C. ruminantium (MAP 1), E. chaffeensis (OMP-1), and the agent of HGE (GE MSP-2 and HGE-44), are candidate vaccine antigens (28, 30, 31). Our results are thus directly relevant for the potential use of ehrlichial OMP as immunogens for ehrlichial pathogens of humans and domestic animals (14, 18, 27, 28, 30, 36, 51, 53).
The requirement for five immunizations to detect antigen-specific proliferation is likely due to the use of alum, which is a poor adjuvant. When either RIBI or complete Freund's adjuvant was used with a comparable amount of protein antigen from Babesia bigemina (37) or A. marginale (MSP-1) (W. C. Brown, T. C. McGuire, and G. H. Palmer, unpublished observations), specific proliferative responses were detected after three antigen inoculations. Additionally, when cattle were immunized with A. marginale membranes in saponin, responses were detected after two or three inoculations (7).
This study also demonstrates the adjuvant effect of IL-12 in priming
for enhanced memory IgG and type 1 cytokine responses to A. marginale MSP-2. Alum was used with IL-12, since in mice alum
fails to elicit a type-1 response, permitting an evaluation of the
effects of IL-12, and because it appeared to prolong the in vivo effect
of IL-12 (19). IL-12 promotes type-1 responses in several
ways (reviewed in reference 16). First, IL-12
produced by the major APC, the dendritic cell, acts on naïve Th
cells during antigen priming, causing them to differentiate into Th1 cells that secrete high levels of IFN-
upon stimulation. Second, as
a costimulator, IL-12 potentiates the secretion of IFN-
by differentiated T cells in response to specific antigen. Finally, IL-12
stimulates the differentiation of IFN-
-producing effector cells from
memory cells when cultured with the priming antigen. Our studies with
bovine CD4+ T cells have also shown the ability of IL-12 to
enhance IFN-
production by antigen-stimulated Th0 and Th1 clones,
and to promote the differentiation of IFN-
-producing effector cells
from resting PBMC-derived lymphocytes that were subsequently cultured
for several weeks with antigen (4, 49). However, the results
presented here are the first to demonstrate the in vivo effects of
administering IL-12 to cattle as an adjuvant for a soluble protein antigen.
The effects of using IL-12 as an adjuvant during immunization with
MSP-2 were evaluated only after multiple immunizations, so that
immediate effects on priming were not determined. Instead, our
experiments examined the effect of IL-12 on a recall response. As
expected, IL-12 stimulated significantly higher production of IFN-
by LNC draining the MSP-2 injection site and by short-term cultured
CD4+ T-cell lines established from these cells. The
production of IFN-
by the CD4+ T-cell lines indicates
that CD4+ T cells are a source of IFN-
in the LNC. Five-
to tenfold more IFN-
was produced by these cell lines than by the
CD4+ T-cell line established from calf 63 immunized with
MSP-2 alone, or by CD4+ T cell lines from two calves
immunized with A. marginale outer membranes in saponin
(7). These results are consistent with the previously
observed effects of IL-12 on differentiated T-cell clones and on memory
T cells cultured with IL-12 and antigen (4, 49).
Elevated expression of IL-2, IL-4, and IL-10 was also observed in the
IL-12 and MSP-2-immunized calves, demonstrating that IL-12 did not
polarize the response to a strictly Th1 response. IL-10 was similarly
induced by IL-12 following priming in mice or in vitro priming of human
T cells, presumably as a negative-feedback response (16).
Furthermore, immunization with IL-12 supported the development of both
Th1 and Th2 recall responses to keyhole limpet hemocyanin in mice
(3). These mixed Th1 and Th2 cytokine responses were
accompanied by mixed IgG2a and IgG1 responses. Additionally, the
response to a soluble protein antigen adsorbed with alum was shifted
from a Th2-biased response, characterized by predominant IL-4, IL-5,
and IL-10 cytokine and IgG1 antibody responses, to a Th1 response,
marked by increased IFN-
, decreased IL-4, IL-5, and IL-10 responses,
and induction of IgG2a, IgG2b, and IgG3 (19). However,
significantly increased IgG1 titers were observed in the IL-12-treated
mice, suggesting that the regulation of IgG1 in this system was
independent of IL-4.
In cattle, IFN-
enhanced IgG2 production and IL-4 enhanced IgG1
production by B cells activated through T-independent type 2 stimulation (10, 11). Furthermore, the production of IFN-
by CD4+ T-cell clones cultured with antigen and B cells
correlated with IgG2 production by the B cells (6). Based on
this information, we expected to stimulate only IgG1 production with
MSP-2 and alum, and both IgG1 and IgG2 antibody responses with the
combined IL-12-MSP-2-alum formulation. Although a restricted IgG1
response in calves given MSP-2 alone occurred and addition of IL-12
enhanced this response, IL-12 had no consistent effect on IgG2
production. There are several possible explanations for this result.
First, the amount of IL-12 used (three inoculations of 10 µg) may
have been too little in this large animal species to induce sufficient
IFN-
in vivo to facilitate isotype switching. Second, the
development of neutralizing antibodies against human IL-12 may have
prevented the optimal induction of bovine IFN-
and suggests that it
would be preferable to use homologous IL-12. Finally, in cattle,
T-cell-dependent IgG2 production may not be solely dependent on
IFN-
. In support of the latter possibility, Estes et al.
(12) recently demonstrated that when bovine B cells were
costimulated with IL-2, CD40 ligand and anti-surface IgM to mimic
T-cell-dependent activation, the addition of IFN-
enhanced IgG2
production only twofold, whereas type-1 IFN had a greater effect.
Furthermore, in our study the single calf (calf 59) that produced IgG2
was the lowest responder in terms of PBMC proliferation and LNC IL-2
and IFN-
production, again suggesting that factors other than or in
addition to IFN-
are important for IgG2 production.
Enhanced IL-2 production, which was associated with higher levels of
transcript expression and significantly greater proliferation by
antigen-draining LNC, was demonstrated in calves that received IL-12.
This result contrasts that of Jankovic et al. (19), who observed an IFN-
- and NO-dependent suppression of IL-2 production and antigen-induced proliferation of splenocytes from mice immunized with IL-12 and antigen coadsorbed to alum. The suppression was dependent on the dose of IL-12, which supports the possibility that the
amount of IL-12 given in our experiments was not sufficient to induce
suppressive levels of IFN-
. Toxicity with high doses of IL-12 has
been observed in mice and humans (22), but the dosage and
timing of IL-12 administration used in our experiments did not cause
inhibition of bovine lymphocyte responses.
The choice of IL-12 as an adjuvant to induce protection against acute
infection with ehrlichial pathogens, such as A. marginale, is supported by our results. Although the calves in this study were not
challenged, the strong IFN-
response by T-cell lines from calves
protectively immunized with A. marginale outer membranes is
consistent with our hypothesis that protection is in part dependent on
IFN-
production (7, 34). Furthermore, experiments in mice
with related rickettsial organisms demonstrated the importance of
IFN-
and NO in the protective immune response (13, 23, 35). Protection against ehrlichial pathogens may also be mediated by cytophilic antibodies that can facilitate phagocytosis and killing
of the organisms. In cattle both IgG1 and IgG2 subclasses are capable
of in vitro binding to activated macrophages, but only IgG2 had
opsonizing activity for monocytes and neutrophils, suggesting that this
subclass may be more important for phagocytosis in vivo
(25). Although it is still uncertain how bovine IgG2 responses to T-cell-dependent antigens are regulated in vivo, IL-12
should enhance macrophage activation through the induction of IFN-
and aid in clearance of the infection caused by A. marginale and related organisms.
| |
ACKNOWLEDGMENTS |
|---|
We thank Teresa Harkins, Bev Hunter, Emma Karel, and Kim Kegerreis for excellent technical assistance and the Genetics Institute for providing recombinant human IL-12.
This research was supported by research grant no. US-2799-96C from BARD, the United States-Israel Binational Agricultural Research and Development Fund, USDA-NRICGP grant 95-37204-2347, USDA agreement 58-5348-8-004, and NIH NIAID grants R01-AI30136 and R01-AI44005.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA 99164-7040. Phone: (509) 335-6067. Fax: (509) 335-8529. E-mail: wbrown{at}vetmed.wsu.edu.
Present address: Animal Disease Research Unit, ARS/USDA, Washington
State University, Pullman, WA 99164-7030.
Editor: J. M. Mansfield
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Afonso, L. C. C.,
T. M. Scharton,
L. Q. Vieira,
M. Wysocka,
G. Trinchieri, and P. Scott.
1994.
The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.
Science
263:235-237 |
| 2. | Beyer, J. C., R. W. Stich, W. C. Brown, and W. P. Cheevers. 1998. Cloning and expression of caprine interferon-gamma. Gene 210:103-108[CrossRef][Medline]. |
| 3. | Bliss, J., V. Van Cleave, K. Murray, A. Wiencis, M. Ketchum, R. Maylor, T. Haire, C. Resmini, A. K. Abbas, and S. F. Wolf. 1996. IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J. Immunol. 156:887-894[Abstract]. |
| 4. |
Brown, W. C.,
W. C. Davis, and W. Tuo.
1996.
Human IL-12 upregulates proliferation and IFN- production by parasite antigen-stimulated Th cell clones and / T cells of cattle.
Ann. N. Y. Acad. Sci.
795:321-324[Medline].
|
| 5. |
Brown, W. C.,
K. S. Logan,
G. G. Wagner, and C. L. Tetzlaff.
1991.
Cell-mediated immune responses to Babesia bovis antigens in cattle following infection with tick-derived or cultured parasites.
Infect. Immun.
59:2418-2426 |
| 6. |
Brown, W. C.,
T. F. McElwain,
G. H. Palmer,
S. E. Chantler, and D. M. Estes.
1999.
Bovine CD4+ T-lymphocyte clones specific for rhoptry-associated protein 1 of Babesia bigemina stimulate enhanced immunoglobulin G1 (IgG1) and IgG2 synthesis.
Infect. Immun.
67:155-164 |
| 7. |
Brown, W. C.,
V. Shkap,
D. Zhu,
T. C. McGuire,
W. Tuo,
T. F. McElwain, and G. H. Palmer.
1998.
CD4+ T-lymphocyte and immunoglobulin G2 responses in calves immunized with Anaplasma marginale outer membranes and protected against homologous challenge.
Infect. Immun.
66:5406-5413 |
| 8. |
Brown, W. C.,
S. Zhao,
A. C. Rice-Ficht,
K. S. Logan, and V. M. Woods.
1992.
Bovine helper T cell clones recognize five distinct epitopes on Babesia bovis merozoite antigens.
Infect. Immun.
60:4364-4372 |
| 9. |
Brown, W. C.,
D. Zhu,
V. Shkap,
T. C. McGuire,
E. F. Blouin,
K. M. Kocan, and G. H. Palmer.
1998.
The repertoire of Anaplasma marginale antigens recognized by CD4+ T-lymphocyte clones from protectively immunized cattle is diverse and includes major surface protein 2 (MSP-2) and MSP-3.
Infect. Immun.
66:5414-5422 |
| 10. |
Estes, D. M.,
N. M. Closser, and G. K. Allen.
1994.
IFN- stimulates IgG2 production from bovine B cells costimulated with anti-µ and mitogen.
Cell. Immunol.
154:287-295[CrossRef][Medline].
|
| 11. | Estes, D. M., A. Hirano, V. T. Heussler, D. A. E. Dobbelaere, and W. C. Brown. 1995. Expression and biological activities of bovine interleukin 4: effects of recombinant bovine interleukin 4 on T cell proliferation and B cell differentiation and proliferation in vitro. Cell. Immunol. 163:268-279[CrossRef][Medline]. |
| 12. |
Estes, D. M.,
W. Tuo,
W. C. Brown, and J. Goin.
1998.
Effects of type I/type II interferons and transforming growth factor- on B-cell differentiation and proliferation. Definition of costimulation and cytokine requirements for immunoglobulin synthesis and expression.
Immunology
95:604-611[CrossRef][Medline].
|
| 13. |
Feng, H. M.,
V. L. Popov, and D. H. Walker.
1994.
Depletion of IFN- and TNF- in mice with Rickettsia conorii-infected endothelium: impairment of rickettsicidal nitric oxide production resulting in fatal, overwhelming rickettsial disease.
Infect. Immun.
62:1952-1960 |
| 14. |
French, D. F.,
W. C. Brown, and G. H. Palmer.
1999.
Emergence of Anaplasma marginale antigenic variants during persistent rickettsemia.
Infect. Immun.
67:5834-5840 |
| 15. |
French, D. F.,
T. F. McElwain,
T. C. McGuire, and G. H. Palmer.
1998.
Expression of Anaplasma marginale major surface protein 2 variants during persistent cyclic rickettsemia.
Infect. Immun.
66:1200-1207 |
| 16. | Gately, M. K., L. M. Renzetti, J. Magram, A. S. Stern, L. Adorini, U. Gubler, and D. H. Presky. 1998. The interleukin-12/interleukin-12 receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16:495-521[CrossRef][Medline]. |
| 17. |
Hsieh, C.,
S. E. Macatonia,
C. S. Tripp,
S. E. Wolf,
A. O'Garra, and K. M. Murphy.
1993.
Listeria-induced Th1 development in ![]() -TCR transgenic CD4+ T cells occurs through macrophage production of IL-12.
Science
260:547-549 |
| 18. |
Ijdo, J. W.,
W. Un,
Y. Zhang,
L. A. Magnarelli, and E. Fikrig.
1998.
Cloning of the gene encoding the 44-kilodalton antigen of the agent of human granulocytic ehrlichiosis and characterization of the response.
Infect. Immun.
66:3264-3269 |
| 19. |
Jankovic, D.,
P. Caspar,
M. Zweig,
M. Garcia-Moll,
S. D. Showalter,
F. R. Vogel, and A. Sher.
1997.
Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV gp120.
J. Immunol.
159:2409-2417 |
| 20. | Johnson, W. C., C. W. Cluff, W. L. Goff, and C. R. Wyatt. 1996. Reactive oxygen and nitrogen intermediates and products from polyamine degradation are babesiacidal in vitro. Ann. N. Y. Acad. Sci. 791:136-147[Medline]. |
| 21. | Knowles, D., S. Torioni de Echaide, G. Palmer, T. McGuire, D. Stiller, and T. McElwain. 1996. Antibody against Anaplasma marginale MSP5 epitope common to tick and erythrocyte stages identifies persistently infected cattle. J. Clin. Microbiol. 34:2225-2230[Abstract]. |
| 22. | Lamont, A. G., and L. Adorini. 1996. IL-12: a key cytokine in immune regulation. Immunol. Today 17:214-217[CrossRef][Medline]. |
| 23. |
Li, H.,
T. R. Jerrels,
G. L. Spitalny, and D. H. Walker.
1987.
Gamma interferon as a crucial defense against Rickettsia conorii in vivo.
Infect. Immun.
55:1252-1255 |
| 24. | Macatonia, S. E., N. A. Hosken, M. Litton, P. Vieira, C.-S. Hsieh, J. A. Culpepper, M. Wysocka, G. Trinchieri, K. M. Murphy, and A. O'Garra. 1995. Dendritic cells produce IL-12 and direct the development of Th1 cells from naïve CD4+ T cells. J. Immunol. 154:5071-5079[Abstract]. |
| 25. | McGuire, T. C., A. J. Musoke, and T. Kurtti. 1979. Functional properties of bovine IgG1 and IgG2: interaction with complement, macrophages, neutrophils, and skin. Immunology 38:249-256[Medline]. |
| 26. | Miller, M. A., M. J. Skeen, and H. K. Ziegler. 1998. Long-lived protective immunity to Listeria is conferred by immunization with particulate or soluble listerial antigen preparations coadministered with IL-12. Cell. Immunol. 184:92-104[CrossRef][Medline]. |
| 27. |
Murphy, C. I.,
J. R. Storey,
J. Recchia,
L. A. Doros-Richert,
C. Gingrich-Baker,
K. Munroe,
J. S. Bakken,
R. T. Coughlin, and G. A. Beltz.
1998.
Major antigenic proteins of the agent of human granulocytic ehrlichiosis are encoded by members of a multigene family.
Infect. Immun.
66:3711-3718 |
| 28. | Nyika, A., S. M. Mahan, M. J. Burridge, T. C. McGuire, F. Rurangirwa, and A. F. Barbet. 1998. A DNA vaccine protects mice against the rickettsial agent Cowdria ruminantium. Parasite Immunol. 20:111-119[CrossRef][Medline]. |
| 29. |
Oberle, S. M.,
G. H. Palmer,
A. F. Barbet, and T. C. McGuire.
1988.
Molecular size variation in an immunoprotective protein complex among isolates of Anaplasma marginale.
Infect. Immun.
56:1567-1573 |
| 30. |
Ohashi, N.,
N. Zhi,
Y. Zhang, and Y. Rikihisa.
1998.
Immunodominant major outer membrane proteins of Ehrlichia chaffeensis are encoded by a polymorphic gene family.
Infect. Immun.
66:132-139 |
| 31. | Palmer, G. H., G. Eid, A. F. Barbet, T. C. McGuire, and T. F. McElwain. 1994. The immunoprotective Anaplasma marginale major surface protein 2 (MSP-2) is encoded by a polymorphic multigene family. Infect. Immun. 62:3803-3816. |
| 32. | Palmer, G. H., and T. F. McElwain. 1995. Molecular basis for vaccine development against anaplasmosis and babesiosis. Vet. Parasitol. 57:233-253[CrossRef][Medline]. |
| 33. | Palmer, G. H., and T. C. McGuire. 1984. Immune serum against Anaplasma marginale initial bodies neutralizes infectivity for cattle. J. Immunol. 133:1010-1015[Abstract]. |
| 34. | Palmer, G. H., F. R. Rurangirwa, K. M. Kocan, and W. C. Brown. 1999. Molecular basis for vaccine development against the ehrlichial pathogen Anaplasma marginale. Parasitol. Today 15:281-286[CrossRef][Medline]. |
| 35. |
Park, J., and Y. Rikihisa.
1992.
L-Arginine-dependent killing of intracellular Ehrlichia risticii by macrophages treated with gamma interferon.
Infect. Immun.
60:3504-3508 |
| 36. | Reddy, G. R., C. R. Sulsona, A. F. Barbet, S. M. Mahan, M. J. Burridge, and A. R. Alleman. 1998. Molecular characterization of a 28 kDa surface antigen gene family of the tribe Ehrlichiae. Biochem. Biophys. Res. Commun. 247:636-643[CrossRef][Medline]. |
| 37. | Rodriguez, S. D., G. H. Palmer, T. F. McElwain, T. C. McGuire, B. J. Ruef, C. G. Chitko-McKown, and W. C. Brown. 1996. CD4+ T-helper lymphocyte responses against Babesia bigemina rhoptry-associated protein 1. Infect. Immun. 64:2079-2087[Abstract]. |
| 38. | Ruef, B. J., W. Tuo, S. D. Rodriguez, A. J. Roussel, C. G. Chitko-McKown, G. H. Palmer, T. F. McElwain, A. Canals, D. S. Zarlenga, L. C. Gasbarre, and W. C. Brown. 1997. Immunization with Babesia bigemina rhoptry-associated protein 1 induces a type 1 cytokine response. J. Interferon Cytokine Res. 17:45-54[Medline]. |
| 39. |
Rurangirwa, F. R.,
D. Stiller,
D. M. French, and G. H. Palmer.
1999.
Restriction of major surface protein 2 (MSP2) variants during tick transmission of the ehrlichia Anaplasma marginale.
Proc. Natl. Acad. Sci. USA
96:3171-3176 |
| 40. |
Scott, P.
1993.
IL-12: initiation cytokine for cell-mediated immunity.
Science
260:496-497 |
| 41. |
Seder, R. A.,
R. Gazzinelli,
A. Sher, and W. E. Paul.
1993.
Interleukin 12 acts directly on CD4+ T cells to enhance priming for IFN production and diminishes IL-4 inhibition of such priming.
Proc. Natl. Acad. Sci. USA
90:10188-10192 |
| 42. |
Shoda, L. K. M.,
D. S. Zarlenga,
A. Hirano, and W. C. Brown.
1999.
Cloning of a cDNA encoding bovine interleukin 18 (IL-18) and analysis of IL-18 expression in macrophages and its IFN- -inducing activity.
J. Interferon Cytokine Res.
19:1169-1177[CrossRef][Medline].
|
| 43. |
Sousa, C. R.,
S. Hieny,
T. Scharton-Kersten,
D. Jankovic,
H. Charest,
R. N. Germain, and A. Sher.
1997.
In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin-12 by dendritic cells and their redistribution to T cell areas.
J. Exp. Med.
186:1799-1802 |
| 44. |
Stich, R. W.,
L. K. M. Shoda,
M. Dreewes,
B. Adler,
T. W. Jungi, and W. C. Brown.
1998.
Stimulation of nitric oxide production in macrophages by Babesia bovis.
Infect. Immun.
66:4130-4136 |
| 45. | Stoll, S., H. Jonuleit, E. Schmitt, G. Muller, H. Yamauchi, M. Kurimoto, J. Knop, and A. H. Enk. 1998. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur. J. Immunol. 28:3231-3239[CrossRef][Medline]. |
| 46. |
Tebele, N.,
T. C. McGuire, and G. H. Palmer.
1991.
Induction of protective immunity using Anaplasma marginale initial body membranes.
Infect. Immun.
59:3199-3204 |
| 47. | Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251-276[Medline]. |
| 48. |
Tuo, W.,
F. W. Bazer,
W. C. Davis,
D. Zhu, and W. C. Brown.
1999.
Differential effects of type I IFNs on the growth of WC1 CD8+ ![]() T cells and WC1+ CD8 ![]() T cells in vitro.
J. Immunol.
162:245-253 |
| 49. |
Tuo, W.,
D. M. Estes, and W. C. Brown.
1999.
Comparative effects of IL-12 and IL-4 on cytokine responses by antigen-stimulated memory CD4+ T cells of cattle: IL-12 enhances IFN- production, whereas IL-4 has marginal effects on cytokine expression.
J. Interferon Cytokine Res.
19:743-751.
|
| 50. |
Tuo, W.,
H. Macmillan,
N. Günter,
F. W. Bazer, and W. C. Brown.
1999.
Upregulation of IL-4 and IFN- expression by interferon- , a member of the type I IFN family.
J. Interferon Cytokine Res.
19:179-187[CrossRef][Medline].
|
| 51. |
van Vliet, A. H. M.,
F. Jongejan,
M. van Kleef, and B. A. M. van der Zeijst.
1994.
Molecular cloning, sequence analysis, and expression of the gene encoding the immunodominant 32-kilodalton protein of Cowdria ruminantium.
Infect. Immun.
62:1451-1456 |
| 52. | Zarlenga, D. S., A. Canals, and L. Gasbarre. 1995. Method for constructing internal standards for use in competitive PCR. BioTechniques 19:324-326[Medline]. |
| 53. |
Zhi, N.,
N. Ohashi,
Y. Rikihisa,
H. W. Horowitz,
G. P. Wormser, and K. Hechemy.
1998.
Cloning and expression of the 44-kilodalton major outer membrane protein gene of the human granulocytic ehrlichiosis agent and application of the recombinant protein to serodiagnosis.
J. Clin. Microbiol.
36:1666-1673 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»